Antibody Therapeutics

A Review of Conjugation Technologies for Antibody Drug Conjugates

• Abstract

Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate

• Abstract
• Supplementary data

Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors

• Abstract

Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development

• Abstract

A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade

• Abstract

Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality

• Abstract

Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research

• Abstract

Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule

• Abstract
• Supplementary data

Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review

• Abstract

A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency

• Abstract

Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications

• Abstract
• Supplementary data

Practical advice in the development of a lyophilized protein drug product

• Abstract

Connexin 43 hemichannels and related diseases

• Abstract

Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication

• Abstract

Leveraging high-throughput analytics and automation to rapidly develop high-concentration mAb formulations: integrated excipient compatibility and viscosity screening

• Abstract
• Supplementary data

Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform

• Abstract
• Supplementary data

AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains

• Abstract
• Supplementary data

Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma

• Abstract
• Supplementary data

FcRider: a recombinant Fc nanoparticle with endogenous adjuvant activities for hybrid immunization

• Abstract
• Supplementary data